Denosumab for treatment of a recurrent cervical giant-cell tumor

15Citations
Citations of this article
17Readers
Mendeley users who have this article in their library.

Abstract

A 43-year-old male patient with C5 giant cell tumor (GCT) underwent tumor resection and anterior bone fusion of C4-C6. The tumor recurred locally 9 months after surgery with the patient complaining of neck and shoulder pain similar to his preoperative symptoms. Denosumab was administered and his pain disappeared after a two-month administration, with a sclerotic rim formation seen at the tumor site on computed tomography. He has been followed for 18 months with no evidence of tumor recurrence. Complete resection is generally recommended, but is not easy for many patients with cervical GCT because of the existence of neurovascular structures. Some patients suffer from recurrence and treatment becomes more difficult. As such, denosumab may be an efficacious option for treatment of recurrent GCT of the cervical spine, although long-term follow-up is required to monitor for presence or absence of recurrence.

Cite

CITATION STYLE

APA

Kajiwara, D., Kamoda, H., Yonemoto, T., Iwata, S., Ishii, T., Tsukanishi, T., … Okawa, A. (2016). Denosumab for treatment of a recurrent cervical giant-cell tumor. Asian Spine Journal, 10(3), 553–557. https://doi.org/10.4184/asj.2016.10.3.553

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free